Welcome to eBioscience. Tel: 888.999.1371 or 858.642.2058.  San Diego, California, USA.
View cart
Account
Ordering help
MSDS
Home Products Protocols Technical Support About Us Contact Us
Neu (C18) Blocking Peptide
 
Print Page  
 
Adobe PDF
Contents: Neu (C18) Blocking Peptide
Catalog Number: 66-P746
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN3 and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Prices for This Product*
Cat. No. Size Price Qty Action
66-P746-81 50 ug $25
*International customers: Please contact your distributor for region specific pricing.

   

Available Formats of This Product
Cat. No. Format Excite
(nm)
Emit
(nm)
Reported Applications
66-P746 Blocking Peptides for anti-mouse/human/rat Neu polyclonal N/A N/A WB 

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.


Description


This is a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).


Applications Reported


For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.


References



1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7


Related Products


Cat. 14-6746    Purified anti-mouse/human/rat Neu polyclonal (clone Polyclonal)


Home  |   Index  |   Site Map  |   FAQ  |   Terms & Conditions  |   Distributors  |   Careers  |   Contact Us
Copyright © 2000-2008 eBioscience, Inc.
Product For Research Use Only: Not for further distribution without written consent.